In this report we show that prophylactic tocilizumab prior to anti-CD19 CAR-T cells with CD3ζ/4-1BB costimulatory signaling is feasible and is associated with a low incidence of high–grade CRS without an increase in ICANS rates or deleterious impact on cell product efficacy. This evidence concerns the gene CD247 and congenital rubella syndrome.